網路城邦
上一篇 回創作列表 下一篇   字體:
MD 2017下半年推薦股名單(10) : SRPT
2017/07/27 03:01:13瀏覽308|回應0|推薦2

可在$39.21或低進埸購買SRPT,此為生化科技股,我們的目標定為$62-63。祝您好運!            

                           

公司簡介:Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

 

法律聲明:1.投資有風險,務必愼重評估 及 自負後果。

              2. 我目前持有以上股票



( 知識學習商業管理 )
回應 推薦文章 列印 加入我的文摘
上一篇 回創作列表 下一篇

引用
引用網址:http://classic-blog.udn.com/article/trackback.jsp?uid=charlesyuen&aid=107233811